Pfizer slides as 2026 revenue is seen pressured by patent cliffs
TL;DR Summary
Pfizer shares fell in premarket trading after reaffirming its 2026 outlook, projecting roughly a $1.5 billion revenue decline as products lose market exclusivity. The headwind is driven by patent cliffs, tariffs, and about $5 billion in COVID-19 product revenue, even as vaccines and drugs such as Abrysvo, Eliquis, Padcev, and Prevnar show growth.
- Pfizer stock slips after Q4 2025 results (PFE:NYSE) Seeking Alpha
- Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook CNBC
- Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand The Wall Street Journal
- Pfizer Dives After Reaffirming Its Modest Outlook And Providing An Obesity Update Investor's Business Daily
- One cancer drug steps back, and obesity asset steps forward, as Pfizer reports earnings Endpoints News
Reading Insights
Total Reads
1
Unique Readers
5
Time Saved
3 min
vs 3 min read
Condensed
91%
586 → 53 words
Want the full story? Read the original article
Read on Seeking Alpha